Market research
NOVC.F Novo Nordisk A/S
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 407B
- P/E ratio
- 46.17
- Analyst target
- Not available
- Dividend yield
- 1.0%
- Beta
- 0.24
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- DK0062498333
- Market cap
- 407B
- P/E ratio
- 46.17
- Analyst target
- Not available
- Dividend yield
- 1.0%
- Beta
- 0.24
About
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NOVC.F discussion.
5 years, 5 months ago
Novo Nordisk A/S is currently in a long term uptrend where the price is trading 22.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.0.
Novo Nordisk A/S's total revenue sank by 0.9% to $32B since the same quarter in the previous year.
Its net income has increased by 6.9% to $9B since the same quarter in the previous year.
Finally, its free cash flow fell by 161.3% to $-1B since the same quarter in the previous year.
Based on the above factors, Novo Nordisk A/S gets an overall score of 3/5.